)
)
)
Guidant Biotherapeutics
March 02, 2026
Ballroom I C
Type: Company Presentation
Focus Area:
Oncology
Guidant Bio (aka Sonnet Bio) is a clinical stage oncology company with differentiated dual-cytokine and next gen ADC assets built on our clinically validated proprietary tumor-targeting delivery platform. We have spun out all the Sonnet Bio assets after a reverse merger of the publicly listed entity with a crypto company. We see pipeline value inflection milestones at 1, 2 and 3 years with a $20MM to $30MM funding. We are also looking for partnerships for co-development on our next gen ADC targeted delivery platform. Our dual IL-12+IL-15 fusion protein couples with circulating albumin to get actively transported and sequestered in the tumor microenvironment. Synergistic activity of IL12 and 15 gives 2X more potency than IL-12 or IL-15 alone. The phase I clinical data with IL-12 and this targeted delivery platform demonstrates safety at high doses , along with a regulatory pathway for IL-15 in bladder cancer makes this a low risk rapid development approach with POC in 18 mos.
Year Founded:
2026
Lead Product in Development:
GDT-002 Dual Cytokine IL-12+IL-15 on a targeted delivery platform
Speakers
){kind=logo}
)
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
